- Home
- GRNT vs TNGX Comparison
GRNT vs TNGX Comparison
Compare GRNT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNT
- TNGX
- Stock Information
- Founded
- GRNT 2013
- TNGX 2014
- Country
- GRNT United States
- TNGX United States
- Employees
- GRNT N/A
- TNGX N/A
- Industry
- GRNT Blank Checks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- GRNT Finance
- TNGX Health Care
- Exchange
- GRNT Nasdaq
- TNGX Nasdaq
- Market Cap
- GRNT 707.4M
- TNGX 723.2M
- IPO Year
- GRNT N/A
- TNGX N/A
- Fundamental
- Price
- GRNT $5.52
- TNGX $7.62
- Analyst Decision
- GRNT Buy
- TNGX Strong Buy
- Analyst Count
- GRNT 2
- TNGX 6
- Target Price
- GRNT $7.50
- TNGX $10.00
- AVG Volume (30 Days)
- GRNT 529.9K
- TNGX 1.5M
- Earning Date
- GRNT 11-06-2025
- TNGX 11-05-2025
- Dividend Yield
- GRNT 7.93%
- TNGX N/A
- EPS Growth
- GRNT N/A
- TNGX N/A
- EPS
- GRNT 0.25
- TNGX N/A
- Revenue
- GRNT $409,332,000.00
- TNGX $24,296,000.00
- Revenue This Year
- GRNT $34.49
- TNGX $20.42
- Revenue Next Year
- GRNT $13.97
- TNGX N/A
- P/E Ratio
- GRNT $22.56
- TNGX N/A
- Revenue Growth
- GRNT 10.32
- TNGX N/A
- 52 Week Low
- GRNT $4.52
- TNGX $1.03
- 52 Week High
- GRNT $7.00
- TNGX $9.84
- Technical
- Relative Strength Index (RSI)
- GRNT 53.78
- TNGX 63.92
- Support Level
- GRNT $5.31
- TNGX $6.38
- Resistance Level
- GRNT $5.47
- TNGX $6.90
- Average True Range (ATR)
- GRNT 0.17
- TNGX 0.45
- MACD
- GRNT 0.01
- TNGX 0.05
- Stochastic Oscillator
- GRNT 64.71
- TNGX 80.12
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.